Two trastuzumab-based ADCs have been designed to target HER2, a key oncogenic driver in a subset of NSCLC, combining a monoclonal antibody directed against HER2 with two different cytotoxic payloads, enabling selective delivery of chemotherapy to HER2-positive tumor cells while minimizing off-target effects. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.